Balchem Corporation
BCPCBasic MaterialsNASDAQSpecialty Chemicals
Scan Results
Daily timeframeHeadquartered within the basic materials sector, Balchem Corporation focuses on Specialty Chemicals services and products. Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization,. The $5.44B market capitalization puts BCPC squarely in mid-cap range for its industry. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Market Cap
$5.44B
Beta
0.81
P/E (TTM)
33.57
P/E (Fwd)
27.19
EPS (TTM)
$5.08
EPS (Fwd)
$6.27
ROE
12.8%
ROA
8.2%
Cash
$63.2M
Total Debt
$166.7M
Free CF
$134.8M
52W Change
10.3%
Annual Financials
Cash vs Debt
Where BCPC stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, BCPC finished 6.20% above its 150-day moving average ($169.30) and 8.34% above its 200-day moving average ($165.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BCPC overbought or oversold?
At the August 27, 2026 close, BCPC's RSI(14) was 48.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Balchem Corporation carries $166.7M in total debt against $63.2M in cash reserves — debt is roughly 2.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $134.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 12.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $942.4M to $1.04B.
As with any equity investment, BCPC carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing BCPC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.